DE602004024668D1 - CaSR-ANTAGONIST - Google Patents
CaSR-ANTAGONISTInfo
- Publication number
- DE602004024668D1 DE602004024668D1 DE602004024668T DE602004024668T DE602004024668D1 DE 602004024668 D1 DE602004024668 D1 DE 602004024668D1 DE 602004024668 T DE602004024668 T DE 602004024668T DE 602004024668 T DE602004024668 T DE 602004024668T DE 602004024668 D1 DE602004024668 D1 DE 602004024668D1
- Authority
- DE
- Germany
- Prior art keywords
- casr antagonist
- casr
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 title 1
- 101710159793 Extracellular calcium-sensing receptor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003119131 | 2003-04-23 | ||
PCT/JP2004/005886 WO2004094362A1 (ja) | 2003-04-23 | 2004-04-23 | CaSRアンタゴニスト |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004024668D1 true DE602004024668D1 (de) | 2010-01-28 |
Family
ID=33308093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004024668T Expired - Lifetime DE602004024668D1 (de) | 2003-04-23 | 2004-04-23 | CaSR-ANTAGONIST |
Country Status (31)
Country | Link |
---|---|
US (4) | US7304174B2 (de) |
EP (3) | EP2189439A3 (de) |
JP (1) | JP3751312B2 (de) |
KR (1) | KR100696927B1 (de) |
CN (2) | CN100577633C (de) |
AR (1) | AR044075A1 (de) |
AT (1) | ATE452121T1 (de) |
AU (1) | AU2004232604C1 (de) |
BR (1) | BRPI0407097A (de) |
CA (1) | CA2513738C (de) |
CL (1) | CL2004000868A1 (de) |
CO (1) | CO5640091A2 (de) |
CY (1) | CY1109880T1 (de) |
DE (1) | DE602004024668D1 (de) |
DK (1) | DK1619180T3 (de) |
ES (1) | ES2337576T3 (de) |
HK (1) | HK1083096A1 (de) |
HR (1) | HRP20100042T1 (de) |
IL (1) | IL169575A (de) |
MX (1) | MXPA05007609A (de) |
MY (1) | MY138734A (de) |
NO (1) | NO20054868L (de) |
NZ (1) | NZ541188A (de) |
PE (1) | PE20050460A1 (de) |
PL (1) | PL1619180T3 (de) |
PT (1) | PT1619180E (de) |
RU (1) | RU2315036C2 (de) |
SI (1) | SI1619180T1 (de) |
TW (1) | TWI329628B (de) |
WO (1) | WO2004094362A1 (de) |
ZA (1) | ZA200505587B (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
JPWO2004106280A1 (ja) * | 2003-05-28 | 2006-07-20 | 日本たばこ産業株式会社 | CaSRアンタゴニスト |
EP1713758A4 (de) * | 2004-02-06 | 2008-02-13 | Smithkline Beecham Corp | Kalzilytische verbindungen |
CN101437490A (zh) | 2006-04-20 | 2009-05-20 | 安美基公司 | 稳定乳液配方 |
EP2139462B1 (de) | 2007-03-30 | 2014-01-22 | Amgen Inc. | Calcimimetische verbindungen zur verwendung bei der behandlung von darmerkrankungen |
DK2292592T3 (da) | 2008-06-05 | 2012-10-08 | Asahi Kasei Pharma Corp | Sulfonamidforbindelse og anvendelse deraf |
CN102307852B (zh) | 2008-12-24 | 2013-12-18 | 第一三共株式会社 | 环状胺化合物 |
CA2748250A1 (en) | 2008-12-24 | 2010-07-01 | Daiichi Sankyo Company, Limited | Indanyl compounds |
WO2010103429A1 (en) * | 2009-03-10 | 2010-09-16 | Pfizer Inc. | 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists |
WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
EP2412697A1 (de) | 2009-03-26 | 2012-02-01 | Japan Tobacco, Inc. | Verfahren zur herstellung einer carboxylsäureverbindung |
WO2010113860A1 (ja) * | 2009-03-31 | 2010-10-07 | 第一三共株式会社 | ビフェニル-環状アミン化合物 |
CA2762130A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
EP2435404A1 (de) | 2009-05-27 | 2012-04-04 | Leo Pharma A/S | Neue, calciumempfindliche rezeptoren modulierende verbindungen und deren pharmazeutische verwendung |
EP2643298A1 (de) | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Substituierte cyclopentylazine als casr-aktive verbindungen |
EP2643292A1 (de) | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Casr-aktive verbindungen |
US20130244995A1 (en) | 2010-11-26 | 2013-09-19 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
CN103270018A (zh) | 2010-11-26 | 2013-08-28 | 利奥制药有限公司 | 钙敏感受体激活化合物 |
GB201113538D0 (en) * | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
AU2013308081A1 (en) * | 2012-08-27 | 2015-02-26 | Lupin Atlantis Holdings Sa | Arylalkylamine compounds as calcium sensing receptor modulators |
CN109562089A (zh) | 2016-06-13 | 2019-04-02 | 心悦生医股份有限公司 | 苯甲酸锂用于治疗中枢神经系统疾病的用途 |
AU2020399030A1 (en) * | 2019-12-09 | 2022-06-23 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Calcium-sensing receptor agonist compound and application thereof |
MX2023001438A (es) | 2020-08-04 | 2023-06-15 | Calcilytix Therapeutics Inc | Formulaciones de compuestos calciliticos de trifenilo. |
JP2023542932A (ja) * | 2020-09-18 | 2023-10-12 | カルシリティクス セラピューティクス,インコーポレイティド | 常染色体優性低カルシウム血症1型(adh1)の治療のためのトリフェニルカルシリティック化合物 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE633760A (de) * | 1963-06-18 | |||
DD207203A1 (de) * | 1982-06-21 | 1984-02-22 | Peter Meisel | Verfahren zur herstellung von epoxypropylethern |
DE3743265A1 (de) * | 1987-12-19 | 1989-06-29 | Boehringer Ingelheim Kg | Neue ammoniumverbindungen, ihre herstellung und verwendung |
US5276008A (en) * | 1990-08-09 | 1994-01-04 | Bayer Aktiengesellschaft | Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones |
WO1997037967A1 (en) | 1996-04-09 | 1997-10-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
US6818660B2 (en) | 1996-04-09 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
EP0827746B1 (de) * | 1996-09-05 | 2002-04-03 | Eli Lilly And Company | Carbazolanaloge als selektive beta3-adrenergische Agonisten |
UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
AR014975A1 (es) | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
US20020052509A1 (en) | 1998-04-08 | 2002-05-02 | Smithkline Beecham Corporation | Calcilytic compounds and method of use |
PE20000415A1 (es) | 1998-04-08 | 2000-05-21 | Smithkline Beecham Corp | Compuestos calciliticos |
US6334338B1 (en) | 1998-07-02 | 2002-01-01 | Lucent Technologies Inc. | Sol gel process of making a fiber preform with removal of oxide particles |
WO2000009132A1 (en) | 1998-08-12 | 2000-02-24 | Smithkline Beecham Corporation | Calcilytic compounds |
US6335338B1 (en) | 1998-08-12 | 2002-01-01 | Smithkline Beecham Corporation | Calcilytic compounds |
ID28276A (id) * | 1998-10-23 | 2001-05-10 | Hoffmann La Roche | Heterolingkar nitrogen bisiklik |
PE20001456A1 (es) | 1999-02-02 | 2001-01-28 | Smithkline Beecham Corp | Compuestos calcioliticos |
MXPA02002129A (es) * | 1999-08-27 | 2002-09-18 | Procter & Gamble | Componentes de formulacion de accion rapida, composiciones y metodos para lavanderia que los emplean. |
IL139073A0 (en) | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
AR030684A1 (es) | 2000-01-24 | 2003-09-03 | Smithkline Beecham Corp | Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos |
US20030018203A1 (en) | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
US6867299B2 (en) * | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
CA2416537A1 (en) | 2000-07-21 | 2002-01-31 | Smithkline Beecham Corporation | Calcilytic compounds |
WO2002014259A1 (fr) * | 2000-08-11 | 2002-02-21 | Japan Tobacco Inc. | Antagonistes du recepteur de calcium |
EP1404654A4 (de) | 2000-10-25 | 2008-12-03 | Smithkline Beecham Corp | Kalzilytische verbindungen |
ATE343390T1 (de) | 2000-10-25 | 2006-11-15 | Smithkline Beecham Corp | Kalzilytische verbindungen |
AR038658A1 (es) | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
US6864267B2 (en) | 2001-07-16 | 2005-03-08 | Smithkline Beecham Corporation | Calcilytic compounds |
JPWO2004106280A1 (ja) * | 2003-05-28 | 2006-07-20 | 日本たばこ産業株式会社 | CaSRアンタゴニスト |
-
2004
- 2004-04-23 EP EP09177717A patent/EP2189439A3/de not_active Withdrawn
- 2004-04-23 RU RU2005123985/04A patent/RU2315036C2/ru not_active IP Right Cessation
- 2004-04-23 PT PT04729243T patent/PT1619180E/pt unknown
- 2004-04-23 EP EP04729243A patent/EP1619180B1/de not_active Expired - Lifetime
- 2004-04-23 NZ NZ541188A patent/NZ541188A/en not_active IP Right Cessation
- 2004-04-23 PL PL04729243T patent/PL1619180T3/pl unknown
- 2004-04-23 AR ARP040101388A patent/AR044075A1/es unknown
- 2004-04-23 MX MXPA05007609A patent/MXPA05007609A/es active IP Right Grant
- 2004-04-23 CN CN200480002843A patent/CN100577633C/zh not_active Expired - Fee Related
- 2004-04-23 CN CN200910253477A patent/CN101723921A/zh active Pending
- 2004-04-23 DK DK04729243.8T patent/DK1619180T3/da active
- 2004-04-23 ZA ZA200505587A patent/ZA200505587B/en unknown
- 2004-04-23 AU AU2004232604A patent/AU2004232604C1/en not_active Ceased
- 2004-04-23 WO PCT/JP2004/005886 patent/WO2004094362A1/ja active Application Filing
- 2004-04-23 ES ES04729243T patent/ES2337576T3/es not_active Expired - Lifetime
- 2004-04-23 TW TW093111360A patent/TWI329628B/zh not_active IP Right Cessation
- 2004-04-23 KR KR1020057013977A patent/KR100696927B1/ko not_active IP Right Cessation
- 2004-04-23 MY MYPI20041512A patent/MY138734A/en unknown
- 2004-04-23 PE PE2004000403A patent/PE20050460A1/es not_active Application Discontinuation
- 2004-04-23 JP JP2005505801A patent/JP3751312B2/ja not_active Expired - Lifetime
- 2004-04-23 US US10/830,480 patent/US7304174B2/en active Active
- 2004-04-23 DE DE602004024668T patent/DE602004024668D1/de not_active Expired - Lifetime
- 2004-04-23 AT AT04729243T patent/ATE452121T1/de active
- 2004-04-23 CL CL200400868A patent/CL2004000868A1/es unknown
- 2004-04-23 BR BR0407097-6A patent/BRPI0407097A/pt not_active IP Right Cessation
- 2004-04-23 SI SI200431348T patent/SI1619180T1/sl unknown
- 2004-04-23 EP EP10179435.2A patent/EP2308828A3/de not_active Withdrawn
- 2004-04-23 CA CA2513738A patent/CA2513738C/en not_active Expired - Fee Related
-
2005
- 2005-07-07 IL IL169575A patent/IL169575A/en not_active IP Right Cessation
- 2005-10-19 CO CO05106148A patent/CO5640091A2/es active IP Right Grant
- 2005-10-21 NO NO20054868A patent/NO20054868L/no not_active Application Discontinuation
-
2006
- 2006-05-10 HK HK06105438.3A patent/HK1083096A1/xx not_active IP Right Cessation
-
2007
- 2007-08-17 US US11/840,739 patent/US20080255042A1/en not_active Abandoned
-
2009
- 2009-03-27 US US12/412,964 patent/US20090326058A1/en not_active Abandoned
-
2010
- 2010-01-22 HR HR20100042T patent/HRP20100042T1/hr unknown
- 2010-03-10 CY CY20101100234T patent/CY1109880T1/el unknown
-
2011
- 2011-12-23 US US13/336,205 patent/US20120301552A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054868D0 (no) | CaSr antagonist | |
ATE363383T1 (de) | Schlingenware | |
DE502004001683D1 (de) | Kabelführung | |
DE602004031845D1 (de) | Ng | |
AT502792A5 (de) | Düsenanpressvorrichtung | |
DE112004000620D2 (de) | Struktoguss | |
DE502004000672D1 (de) | Pigmentpreparationen | |
DE502004001524D1 (de) | Hydrolager | |
ATA662003A (de) | Trink-mundstück | |
DE602004018799D1 (de) | Ng | |
ATE446959T1 (de) | Chromenonindole | |
DE502004001629D1 (de) | Bremsenprüfstand | |
DE502004003122D1 (de) | Hydrolager | |
DK1633719T3 (da) | Substituerede spirobenzazepiner | |
DE502004002978D1 (de) | N-biarylamide | |
DE502004000518D1 (de) | Mitgängergabelhubwagen | |
DE10394329D2 (de) | Mäanderstent | |
DE10355350A8 (de) | Elektromodul | |
ATE406350T1 (de) | Prolinylarylacetamide | |
DE112004002227D2 (de) | Nietverarbeitungsgerät | |
DE10329218B4 (de) | Hotflue | |
DE502004002771D1 (de) | Umlenkhebel | |
DE112004001561D2 (de) | Getriebene-Antreibseinheit | |
DE502004002619D1 (de) | Flaschenverschluss | |
DE20317661U1 (de) | Faltkleiderschrank |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |